JD
Therapeutic Areas
Janux Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| JANX007 | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 |
| JANX008 | EGFR-positive Solid Tumors | Phase 1 |
| JANX011 | Autoimmune Diseases | Phase 1 |
| PSMA-TRACIr | mCRPC | IND-Enabling |
| Merck TRACTr Program 1 | Undisclosed | Phase 1 |
| Merck TRACTr Program 2 | Undisclosed | Discovery |
| BMS TRACTr Program | Undisclosed | Discovery |
Leadership Team at Janux Therapeutics
DC
David Campbell, Ph.D.
Founder, President & Chief Executive Officer
TD
Tommy DiRaimondo, Ph.D.
Chief Scientific Officer
WG
William Go, M.D., Ph.D.
Chief Medical Officer
JD
Janeen Doyle
Chief Corporate and Business Development Officer
CW
Charles Winter
Chief Technical Officer
CC
Carolina Caffaro, Ph.D.
Vice President, CMC Process Development
JP
James Pennington
General Counsel
RB
Ron Barrett, Ph.D.
Chairperson of the Board
ED
Eric Dobmeier, J.D.
Board Member
SG
Sheila Gujrathi, M.D.
Board Member